Enliven Therapeutics, Inc.
ELVN
$58.82
$0.761.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.28% | 39.02% | 42.17% | 27.48% | 38.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.90% | 5.01% | 14.45% | 13.30% | 20.30% |
| Operating Income | -8.90% | -5.01% | -14.45% | -13.30% | -20.30% |
| Income Before Tax | -5.70% | -4.42% | -16.78% | -14.39% | -21.33% |
| Income Tax Expenses | -- | -- | -- | -100.00% | -100.00% |
| Earnings from Continuing Operations | -5.70% | -4.16% | -16.48% | -14.07% | -20.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.70% | -4.16% | -16.48% | -14.07% | -20.99% |
| EBIT | -8.90% | -5.01% | -14.45% | -13.30% | -20.30% |
| EBITDA | -9.09% | -5.13% | -14.54% | -13.36% | -20.36% |
| EPS Basic | 16.62% | 13.79% | 2.24% | 3.18% | -3.52% |
| Normalized Basic EPS | 16.70% | 14.38% | 2.93% | 2.24% | -6.45% |
| EPS Diluted | 16.62% | 13.79% | 2.24% | 3.18% | -3.52% |
| Normalized Diluted EPS | 16.70% | 14.38% | 2.93% | 2.24% | -6.45% |
| Average Basic Shares Outstanding | 26.46% | 21.89% | 20.30% | 19.27% | 16.25% |
| Average Diluted Shares Outstanding | 26.46% | 21.89% | 20.30% | 19.27% | 16.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |